Delayed gadolinium enhancement during MR imaging of cartilage of the metacarpophalangeal joints in patients with rheumatoid arthritis is feasible at 3T and may help predict rheumatoid arthritis.
Delayed gadolinium enhancement during MR imaging of cartilage of the metacarpophalangeal joints in patients with rheumatoid arthritis is feasible at 3T and may help predict rheumatoid arthritis.
The procedure involves T1 mapping following intravenous contrast. Concentration of the contrast in cartilage is an indirect measure of glycosaminoglycan (GAG), a component of hyaline cartilage.
The absence of GAG during delayed-contrast MR may help assess cartilage degeneration in the morphologically normal-appearing second and third metacarpophalangeal joints in patients.
Phalangeal and metacarpal delayed-enhancement values in patients with rheumatoid arthritis were significantly lower than in control subjects, although joint thickness was comparable in both groups, according to the researchers. Cartilage damage is a common occurrence in rheumatoid arthritis patients, so imaging may help for diagnosis and treatment purposes (Radiol 2010;257:441-447).
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.